Ipca Laboratories announced that Lyka Labs has allotted to the company 26 lakh equity shares of Rs 10 each representing 7.28% share capital at Rs 139.50 per share including a premium of Rs 129.50 per equity share on conversion of warrants allotted on preferential basis. With this allotment, Ipca Laboratories` shareholding in Lyka Labs is 1,46,24,923 equity shares of Rs. 10/- each representing 40.98% of its paid-up equity share capital, up from 36.34%. Powered by Capital Market - Live News

Ipca Laboratories has appointed Dr Swati Patankar as an Additional Director of the Company with effect from 14 February 2024. Powered by Capital Market - Live News

Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 14 February 2024.Powered by Capital Market - Live News

Ipca Laboratories announced that the Board of Directors of the Company at its meeting held on 10 November 2023, has recommended a Interim dividend of Rs.2 per share (i.e.200%), subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Ipca Laboratories rose 0.81% to Rs 145.06 crore in the quarter ended September 2023 as against Rs 143.90 crore during the previous quarter ended September 2022. Sales rose 27.05% to Rs 2033.96 crore in the quarter ended September 2023 as against Rs 1600.95 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales2033.961600.95 27 OPM %15.8016.22 - PBDT315.70286.63 10 PBT225.36222.89 1 NP145.06143.90 1 Powered by Capital Market - Live News